Clinical trials: Humoral Immunodeficiency
Immunologic Deficiency Syndromes, Neoplasms
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer.
- Trial name
- NCT00001158
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Immune Deficiency
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.
- Trial name
- NCT03968211
- Testing
- Salmonella typhi polysaccharide vaccine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Healthy
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
The lack of clear guidelines and studies addressing the proper response to the pneumococcal vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our immunodeficiency patients.
- Trial name
- NCT00589394
- Testing
- pneumococcal vaccination (Pneumovax)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Covid19, Humoral Acquired Immunodeficiency
Antibody Detection of Vaccine-Induced Secretory Effects
The purpose of this research study is to conduct a prospective longitudinal surveillance research study, enrolling approximately 60 lactating mothers who receive the SARS-CoV-2 vaccine, and then following their clinical and…
- Conditions
- Covid19, Humoral Acquired Immunodeficiency, Coronavirus, SARS-CoV Infection
- Trial name
- ADVISE (NCT04895475)
- Testing
- SARS-CoV-2 vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans